CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 155 enrolled
Drug / intervention
biphasic insulin aspart 30 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01589653
NCT01589653Phase 4Completed
CompareCT.gov

A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin

Novo Nordisk A/S·interventional·Posted May 2, 2012·Updated Jul 11, 2017

In Brief

A Phase 4 clinical trial evaluating biphasic insulin aspart 30 for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 155 participants across 15 sites in 6 countries.

Detailed Summary

This trial is conducted in Africa and Asia. The aim of the trial is to compare patient-adjusted versus physician-adjusted titration of BIAsp 30 combined with metformin in type 2 diabetes patients uncontrolled on NPH insulin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesEgypt, Indonesia, Morocco, Saudi Arabia, Tunisia, Vietnam
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2, 2012
Enrollment StartMay 26, 2012
Primary CompletionJul 9, 2015
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.2 years ago

Interventions

biphasic insulin aspart 30drug

Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.

biphasic insulin aspart 30drug

Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.